A Study Evaluating the Efficacy and Safety of SM04554 Topical Solution in Male Subjects With Androgenetic Alopecia
Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of 0.15% & 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia
In the register
The register attaches this trial to Dalosirvat (SM-04554) (Biosplice Therapeutics), currently at “Phase 2/3” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.
What the registry records
- Status
- Completed
- Declared phase
- Phase 2/3
- Sponsor
- Biosplice Therapeutics, Inc.
- Participants (registry)
- 675
- Start
- November 2018
- Primary completion
- December 2020
- Study completion
- December 2020
- Last registry update
- October 2026
- Countries
- Turkey
Conditions studied: Androgenetic Alopecia
Interventions: Topical SM04554 0.15% solution, Topical SM04554 0.25% solution, Topical vehicle solution
Other trials of Dalosirvat (SM-04554)
A Study of SM04554 Applied Topically to the Scalp of Male Subjects With Androgenetic Alopecia Analyzed by Biopsy of the Scalp Prior To and Post Dosing
A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.